II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Deferred Tax Liabilities (Non-Current)

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

II

ImageneBio Inc Competitors Analysis of Deferred Tax Liabilities (Non-Current)

IMA · NASDAQ
CompanyDeferred Tax Liabilities (Non-Current)
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
0.00
N/AN/AN/A 
4.96M
-34.4%N/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
0.00
N/AN/AN/A
250.00K
-68.0%-30.0%11.2%
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
0.00
N/AN/AN/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
0.00
N/AN/AN/A
0.00
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69